Erik Fiedler

This inventor holds 23 USPTO granted patents and 17 published patent applications, plus 7 CIPO patents and 23 EPO patents, primarily in Binding Proteins. Top assignees: Navigo Proteins Gmbh, Repligen Corporation, Scil Proteins Gmbh. Active years: 2010-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Erik Fiedler. Retrieved from https://idiyas.com/inventor/erik-fiedler

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 (Patent Applications = 17)

% Patents Active = 91.3

CIPO Patents = 7 (Patent Applications = 14)

EPO Patents = 23 (Patent Applications = 39)

Average Co-Inventor Count = 3.1

ph-index = 5

Forward Citations = 75(Granted Patents)

Location History:

Halle, DE (2013)
Halle/Saale, DE (2010 - 2023)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2010-2026

Loading Chart...

Areas of Expertise:

Binding Proteins

Immunoglobulin

Affinity Purification

Polypeptides

Cancer Diagnosis

Ubiquitin

Triple-Helical

Fc Binding

Chemical Moieties

Modified Proteins

Enzyme Binding

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12754184 - BINDING PROTEIN SPECIFIC FOR THE SPIKE PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2) (2026-10-06),

2. 12577276 - IMMUNOGLOBULIN BINDING PROTEINS FOR AFFINITY PURIFICATION (2026-03-17),

3. 12570690 - IMMUNOGLOBULIN BINDING PROTEINS FOR AFFINITY PURIFICATION (2026-03-10),

4. 12552832 - IMMUNOGLOBULIN BINDING POLYPEPTIDES (2026-02-17),

5. 12509493 - NOVEL FOLR1 SPECIFIC BINDING PROTEINS FOR CANCER DIAGNOSIS AND TREATMENT (2025-12-30),

6. 12466857 - NOVEL TRIPLE-HELICAL POLYPEPTIDES LACKING BINDING AFFINITY FOR THE FC DOMAIN OF IMMUNOGLOBULIN AND USES THEREOF (2025-11-11),

7. 12286458 - Binding proteins for the enzyme acid alpha glucosidase (GAA) and uses thereof (2025-04-29),

8. 12275774 - Fc binding proteins with cysteine in the C-terminal helical region (2025-04-14),

9. 12257530 - Fc binding proteins with cysteine in the c-terminal helical region (2025-03-25),

10. 11813336 - Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker (2023-11-14),

11. 11779860 - Fc binding proteins with cysteine in the C-terminal helical region (2023-10-10),

12. 11548929 - Fc binding proteins with cysteine in the c-terminal helical region (2023-01-10),

13. 11414466 - Fusion proteins with specificity for ED-B and long serum half-life for diagnosis or treatment of cancer (2022-08-16),

14. 11230576 - Alkaline stable immunoglobulin-binding proteins (2022-01-25),

15. 11208436 - Populations of polypeptides having a triple-helical structure (2021-12-28),

Title: Exploring the Innovative Mind of Inventor Erik Fiedler

Introduction:

Erik Fiedler, a prolific inventor hailing from Halle/Saale, DE, has made significant contributions to the field of targeted compounds and Fc binding proteins. With an impressive portfolio of 14 patents, Fiedler's work showcases his expertise in developing cutting-edge solutions for site-specific coupling of chemical moieties and affinity purification of immunoglobulins.

Latest Patents:

Fiedler's latest patents include groundbreaking innovations such as targeted compounds for the site-specific coupling of chemical moieties, featuring a unique linking moiety and fusion proteins with ubiquitin muteins. Additionally, his work on Fc binding proteins with cysteine in the C-terminal helical region has revolutionized affinity purification methods for immunoglobulins.

Career Highlights:

Throughout his career, Fiedler has been associated with renowned companies in the industry, including Navigo Proteins GmbH and Scil Proteins GmbH. His expertise and innovative spirit have been instrumental in driving forward the development of novel pharmaceutical solutions and biotechnological advancements.

Collaborations:

Fiedler has had the privilege of collaborating with esteemed professionals in the field, such as Ulrich Haupts and Markus Fiedler. These collaborations have not only enriched his own work but have also contributed to the collective knowledge base of the scientific community.

Conclusion:

Inventor Erik Fiedler's relentless pursuit of innovation and his invaluable contributions to the realm of targeted compounds and Fc binding proteins exemplify the spirit of creativity and excellence in the field of biotechnology. His patents stand as a testament to his dedication to pushing the boundaries of scientific discovery and making a lasting impact on medical applications for the greater good.

Profile summary based on public USPTO records.